Novartis Zelnorm launch
Executive Summary
Novartis Zelnorm (tegaserod) wholesale acquisition cost is $2.05 per 6 mg or 2 mg pill. The irritable bowel syndrome agent was launched Aug. 28 following its July 24 approval (1"The Pink Sheet" July 29, p. 3)...
You may also be interested in...
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.